17:33:12 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-29 Kvartalsrapport 2024-Q2
2024-05-16 Ordinarie utdelning BRAINP 0.00 DKK
2024-05-15 Årsstämma 2024
2024-05-07 Bokslutskommuniké 2023
2023-10-11 Extra Bolagsstämma 2023
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-30 Ordinarie utdelning BRAINP 0.00 DKK
2023-05-26 Årsstämma 2023
2023-04-28 Bokslutskommuniké 2022
2022-09-29 Kvartalsrapport 2022-Q2
2022-09-02 Extra Bolagsstämma 2022
2022-05-19 Ordinarie utdelning BRAINP 0.00 DKK
2022-05-18 Årsstämma 2022
2022-04-29 Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaFirst North Denmark
SektorHälsovård
IndustriVård & Omsorg
Brain+ är verksamma inom läkemedelsbranschen. Bolaget är specialiserade inom forskning och utveckling för behandling av demens och alzheimers. Produktportföljen inkluderar exempelvis kognitiv stimuleringsterapi. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs med störst närvaro inom Europa.
2022-10-27 10:30:00
Copenhagen, Denmark, October 27, 2022 - Brain+ A/S (Nasdaq First North: BRAINP)
  • Rising star clinical dementia researcher to join the company in a new position as Clinical Director
  • Recently, development was also strengthened with a Quality Manager and a Clinical Research Associate
  • The new hires represent a significant competence upgrade and expansion of the clinical team for a more efficient product development and commercialization

Brain+ (BRAINP), a pioneer in the development of digital therapeutics for Alzheimer's disease and dementia, has hired Nahid Zokaei to a new position as Clinical Director, Erik Esmann Poulsen to a new position of Quality Manager, and Lily Anna Mainstone-Cotton as Clinical Research Associate. Nahid will lead the Brain+ clinical pipeline development including academic partnerships. Erik will manage the Brain+ Quality Management Systems and processes, and Lily perform user research to inform R&D.

A team expansion to focus efforts on clinical development and market access

Since August, Brain+ has expanded its team with three new hires within regulatory, clinical, and user research to support the upcoming launch of its first dementia product, CST-Therapist Companion, and plans to launch two additional Cognitive Stimulation Therapy (CST) products. 

Clinical Director - Nahid Zokaei, Ph.D. and Sr. Research Fellow

Nahid Zokaei is a recognized clinical researcher with deep insights into the cognitive decline in Alzheimer's and dementia. She is the author of many high-profile publications in the field and has a particular focus on the primary clinical targets for Brain+' Digital Therapeutic products (DTx), including memory and attention. More specifically, Nahid's research focuses on the development of selective and sensitive tasks to better phenotype cognitive impairments in neurological disorders such as Alzheimer's and Parkinson's disease and in at-risk individuals. Nahid is currently a Senior Research Fellow and University Research Lecturer at the National Institute for Health Research, Dept. of Experimental Psychology & Oxford Centre for Human Brain Activity at the University of Oxford, United Kingdom, and she is a member of the Brain and Cognition Lab.

Quality Manager - Erik Esmann Poulsen, M.Sc.

Erik was a senior regulatory specialist at Medidee Services (now Veranex), a leading European regulatory consultancy, and recently Quality Manager at the Danish Digital Health company, Practio. He will manage the Brain+ Quality Management Systems and processes to ensure the quality and safety of Brain+' products in compliance with regulatory and commercial requirements.

Clinical Research Associate- Lily Anna Mainstone-Cotton, M.Sc. Cognitive Psychology

Lily is a Cognitive Researcher with a strong emphasis on user engagement research and data analytics from digital health companies, Kooth and Okko Health. Lily will be supporting the clinical user needs in R&D, especially around CST for remote use, and analysis of data and real-world evidence from trials and live commercial use.

Simon Nielsen, Chief Science and Innovation Officer, Brain+: "Nahid, Erik, and Lily are strong additions, whom we are very happy to have attracted to our Team. They each come with key competencies that enable us to accelerate clinical development and market access significantly. Nahid is a rising star in the field of cognitive decline research. Her profound understanding of dementia will provide critical input to the development of our technologies and how to build supporting clinical evidence. Erik and Lily both come with strong competencies in their respective fields, critical for marketing regulated products and developing clinically relevant products that users will comply with".

Brain+ Science & Innovation Team now covers all critical Digital Therapeutic R&D needs

With the three new hires, Brain+ has significantly extended its team to have top talent in each key area needed to create and bring to market regulated and reimbursed Digital Therapeutics (DTx). The full Science & Innovation Team now comprises the Chief Science & Innovation Officer, Simon Nielsen, the Clinical Director, Nahid Zokaei, the Innovation Manager, Mia Dong, the Senior Regulatory Manager, Shilpa Ashok Razdan, the Quality Systems Compliance Manager, Erik Esamann Poulsen, and the Clinical Research Associate - Lily Anna Mainstone-Cotton.

Contact Information

CEO, Kim Baden-Kristensen +45 31393317, E-mail: kim@brain-plus.com,Brain+ A/S, Købmagergade 53, 3.